What is it about?
PGLP-1, a newly designed dual-function GLP-1 analog, reduces gluconeogenesis and promotes insulin secretion as well as other GLP-1 agonists.
Featured Image
Why is it important?
We found that PGLP-1, as a bifunctional peptide, can reduce the blood glucose in streptozotocin-induced hyperglycemia mice, so it can be used as adjuvant therapy for T1DM.
Perspectives
I wish to develop long acting of PGLP-1 to a permanent treatment in the future
Dr Murad Alahdal
Johns Hopkins University
Read the Original
This page is a summary of: PGLP-1, a novel long-acting dual-function GLP-1 analog, ameliorates streptozotocin-induced hyperglycemia and inhibits body weight loss, The FASEB Journal, August 2017, Federation of American Societies For Experimental Biology (FASEB),
DOI: 10.1096/fj.201700002r.
You can read the full text:
Contributors
The following have contributed to this page
